Entera Bio Reports $15.6 Million Q3 2026 Net Loss
Entera reported a $15.6 million net loss for Q3 2026, versus $3.2 million a year earlier. The loss included a $7.5 million non-cash warrant remeasurement. Cash and cash equivalents were $265.9 million at September 30; the company expects resources to fund EB613 through topline results and anticipated NDA submission.
Entera reported a Q3 2026 net loss of $15.6M versus $3.2M a year earlier, including a $7.5M non-cash warrant remeasurement. Cash and cash equivalents were $265.9M at September 30; the company expects resources to fund EB613 through topline results and anticipated NDA submission and support operatio…